TWO-YEAR RESULTS FROM THE BIOMATRIX ALPHA REGISTRY PUBLISHED IN JOURNAL OF INTERVENTIONAL CARDIOLOGY
April 29, 2021 | News | BioMatrix Alpha
MACE 7.2% Cardiac Death 1.3% MI 2.8% & ST 1.1%.
CE Mark Approval for Biolimus A9™ Coated Cobalt Chromium Coronary Stent System BioFreedom™ Ultra
October 19, 2020 | News | BioFreedom™ Ultra
BioFreedom™ Ultra is Biosensors International new, novel thin strut CoCr polymer and carrier-free Drug Coated Stent with Biosensors proprietary limus BA9™, a highly lipophilic anti-restenotic drug, developed specifically for use in coronary vascular applications. BioFreedom™ Ultra successfully extends the LEADERS FREE legacy in LEADERS FREE III.